

Workplace Health Health and Safety Well-being

Lentiviral Vector Post Exposure Treatment: After Hours Care

Attention: University Hospital Emergency Department:

- Western employee, graduate student/post doc has been exposed to Lentiviral Vector (3rd and 4th generation)
- Western employee, graduate student/post doc will provide a detailed history of the incident
- Please provide the employee, graduate student/post doc with an assessment, blood testing and treatment as deemed appropriate within the first 2 hours of the incident
- Post exposure medical prophylaxis is recommended in the following 3 scenarios:
 - 1. Direct parenteral inoculation (injection exposure)
 - 2. Contact with mucous membranes or non-intact skin
 - 3. Direct contact at a close range to droplets from an aerosol- generating procedure outside the primary containment
- The recommended treatment for lentivirus is 7 days of a treatment that consists of a
 combination of integrase inhibitor with or without nucleos(t)ide reverse transcriptase
 inhibitors. TREATMENT: Truvada (Tenofovir 300mg and Emtricitabine 200mg) OD +
 Isentress (Raltegravir) 400mg BID, a one-day course is currently available at Workplace
 Health Services
 - Please have the employee, graduate student/post doc sign a consent waiver to have their blood test results sent to Dr. Sidney Siu at Workplace Health, Western University. Fax # 519-661-2016
 - Western employee, graduate student/post doc is responsible for following-up in Workplace Health the next business day

The prompt attention to this incident is appreciated.			
UWO signature:(TR. S.S.U.)	Date: _	Auf 4. 2021	
LHSC signature: Low Lambe	Date:	Au65,2021	
Revised: December 2017, October 2019, July 2021		<i>y</i>	_